NEW YORK – Kura Oncology on Thursday announced a partnership to evaluate its farnesyl transferase inhibitor (FTI) KO-2806 with Mirati Therapeutics' Krazati (adagrasib) in patients with KRAS G12C-mutant non-small cell lung cancer.
Kura will evaluate the combination in its ongoing Phase I trial of KO-2806 monotherapy in advanced solid tumors. Researchers are expected to begin dosing patients with the KO-2806-Krazati combination by mid-2024.
The trial will also include a monotherapy arm for patients with HRAS-mutant tumors; head and neck cancers with HRAS overexpression; KRAS-, NRAS-, or HRAS-mutant NSCLC or colorectal cancer; and KRAS-mutant pancreatic cancer. The firm expects to explore KO-2806 combinations in clear cell renal cell carcinoma alongside the Krazati combination in KRAS G12C-mutant NSCLC.
"Preclinical work demonstrates the ability of adagrasib, in combination with a FTI, to improve patient outcomes," Alan Sandler, chief medical officer at Mirati Therapeutics, said in a statement. "This collaboration exemplifies the potential combinability of adagrasib as a key differentiation from other KRAS G12C inhibitors."
Preclinical research presented by Kura earlier this year demonstrated that the KO-2806-Krazati combination induced tumor regression and had a longer duration and depth of response versus Krazati alone. Researchers also found that the combination had greater signaling inhibition in the MAPK and mTOR pathways, which could address acquired resistance to KRAS G12C inhibitors.